{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:15:37Z","timestamp":1790766937893,"version":"4.1.0"},"reference-count":175,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:00:00Z","timestamp":1655769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institute of Health","award":["1R01 AI139768"],"award-info":[{"award-number":["1R01 AI139768"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>COVID-19 vaccines have been developed to confer immunity against the SARS-CoV-2 infection. Prior to the pandemic of COVID-19 which started in March 2020, there was a well-established understanding about the structure and pathogenesis of previously known Coronaviruses from the SARS and MERS outbreaks. In addition to this, vaccines for various Coronaviruses were available for veterinary use. This knowledge supported the creation of various vaccine platforms for SARS-CoV-2. Before COVID-19 there are no reports of a vaccine being developed in under a year and no vaccine for preventing coronavirus infection in humans had ever been developed. Approximately nine different technologies are being researched and developed at various levels in order to design an effective COVID-19 vaccine. As the spike protein of SARS-CoV-2 is responsible for generating substantial adaptive immune response, mostly all the vaccine candidates have been targeting the whole spike protein or epitopes of spike protein as a vaccine candidate. In this review, we have compiled the immune response to SARS-CoV-2 infection and followed by the mechanism of action of various vaccine platforms such as mRNA vaccines, Adenoviral vectored vaccine, inactivated virus vaccines and subunit vaccines in the market. In the end we have also summarized the various adjuvants used in the COVID-19 vaccine formulation.<\/jats:p>","DOI":"10.3390\/biomedicines10071464","type":"journal-article","created":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T21:55:19Z","timestamp":1655848519000},"page":"1464","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Immune Response to SARS-CoV-2 Vaccines"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0167-3111","authenticated-orcid":false,"given":"Navya","family":"Bellamkonda","sequence":"first","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL 60612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Upendra Pradeep","family":"Lambe","sequence":"additional","affiliation":[{"name":"ICMR-NIV, Mumbai Unit, A. D. Road, Parel, Mumbai 400012, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali","family":"Sawant","sequence":"additional","affiliation":[{"name":"ICMR-NIV, Mumbai Unit, A. D. Road, Parel, Mumbai 400012, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyam Sundar","family":"Nandi","sequence":"additional","affiliation":[{"name":"ICMR-NIV, Mumbai Unit, A. D. Road, Parel, Mumbai 400012, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3958-239X","authenticated-orcid":false,"given":"Chiranjib","family":"Chakraborty","sequence":"additional","affiliation":[{"name":"School of Life Science and Biotechnology, Adamas University, Kolkata 700126, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3039-6953","authenticated-orcid":false,"given":"Deepak","family":"Shukla","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, University of Illinois at Chicago, Chicago, IL 60612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12929-020-00695-2","article-title":"Coronavirus vaccine development: From SARS and MERS to COVID-19","volume":"27","author":"Li","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.chom.2021.06.016","article-title":"The success of SARS-CoV-2 vaccines and challenges ahead","volume":"29","author":"Subbarao","year":"2021","journal-title":"Cell Host Microbe"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s12038-021-00145-7","article-title":"SARS-CoV-2 genomics: An Indian perspective on sequencing viral variants","volume":"46","author":"Srivastava","year":"2021","journal-title":"J. Biosci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1056\/NEJMoa2116063","article-title":"COVID-19 Vaccine Effectiveness in New York State","volume":"386","author":"Rosenberg","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41562-021-01122-8","article-title":"A global database of COVID-19 vaccinations","volume":"5","author":"Mathieu","year":"2021","journal-title":"Nat. Hum. Behav."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1126\/science.abb8923","article-title":"Rapid COVID-19 vaccine development","volume":"368","author":"Graham","year":"2020","journal-title":"Science"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1080\/03079450310001621198","article-title":"Severe acute respiratory syndrome vaccine development: Experiences of vaccination against avian infectious bronchitis coronavirus","volume":"32","author":"Cavanagh","year":"2003","journal-title":"Avian Pathol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"200324","DOI":"10.33590\/emj\/200324","article-title":"Vaccines for COVID-19: Perspectives, prospects, and challenges based on candidate SARS, MERS, and animal coronavirus vaccines","volume":"10","author":"Saif","year":"2020","journal-title":"Eur. Med. J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(03)14962-8","article-title":"Effects of a SARS-associated coronavirus vaccine in monkeys","volume":"362","author":"Gao","year":"2003","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"5975","DOI":"10.1016\/j.vaccine.2014.08.058","article-title":"Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB\/c mice","volume":"32","author":"Kim","year":"2014","journal-title":"Vaccine"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"120586","DOI":"10.1016\/j.ijpharm.2021.120586","article-title":"mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability","volume":"601","author":"Schoenmaker","year":"2021","journal-title":"Int. J. Pharm."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_13","unstructured":"(2022, May 23). Janssen COVID-19 Vaccine, Available online: https:\/\/www.fda.gov\/emergency-preparedness-and-response\/coronavirus-disease-2019-covid-19\/janssen-covid-19-vaccine."},{"key":"ref_14","unstructured":"(2022, May 23). COVID-19 Vaccine AstraZeneca. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/covid-19-vaccine-astrazeneca-product-information-approved-chmp-29-january-2021-pending-endorsement_en.pdf."},{"key":"ref_15","unstructured":"(2022, May 23). Sputnik V Vaccine. Available online: https:\/\/www.precisionvaccinations.com\/vaccines\/sputnik-v-vaccine#:~:text=The%20Sputnik%20V%20vaccine%20is,10*11%20particles%20per%20dose."},{"key":"ref_16","unstructured":"(2022, May 23). Sinovac: COVID-19 Vaccine (Vero Cell Line) Inactivated. Available online: https:\/\/cdn.who.int\/media\/docs\/default-source\/immunization\/sage\/2021\/april\/4_sage29apr2021_sinovac.pdf."},{"key":"ref_17","unstructured":"(2022, May 23). Evidence Assessment: Sinopharm\/BBIBP COVID-19 Vaccine. Available online: https:\/\/cdn.who.int\/media\/docs\/defaultsource\/immunization\/sage\/2021\/april\/2_sage29apr2021_critical-evidence_sinopharm.pdf."},{"key":"ref_18","unstructured":"(2022, May 23). Sinopharm (Vero Cell) Inactivated, COVID-19 Vaccine. Available online: https:\/\/www.who.int\/publications\/m\/item\/sinopharm-vero-cell---inactivated-covid-19-vaccine."},{"key":"ref_19","unstructured":"(2022, May 23). COVAXIN: Factsheet for Recipients and Caregivers. Available online: https:\/\/www.bharatbiotech.com\/images\/covaxin\/covaxin-factsheet.pdf."},{"key":"ref_20","unstructured":"(2022, May 23). EpiVacCorona Vaccine. Available online: https:\/\/www.precisionvaccinations.com\/vaccines\/epivaccorona-vaccine#:~:text=The%20EpiVacCorona%20vaccine%20relies%20on,due%20to%20artificially%20synthesized%20peptides."},{"key":"ref_21","unstructured":"(2022, May 23). MVC-COV1901 VACCINE PROFILE. Available online: https:\/\/cdn.who.int\/media\/docs\/default-source\/blue-print\/developer_medigen_allen-lien.pdf."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa2202261","article-title":"Efficacy and Safety of the RBD-Dimer\u2013Based COVID-19 Vaccine ZF2001 in Adults","volume":"386","author":"Dai","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_23","unstructured":"Precisionvaccinations (2022, May 23). Zifivax (ZF2001) COVID-19 Vaccine. Available online: https:\/\/www.precisionvaccinations.com\/vaccines\/zifivax-zf2001-covid-19-vaccine."},{"key":"ref_24","unstructured":"(2022, May 23). SOBERANA, Cuba\u2019s COVID-19 Vaccine Candidates. Available online: https:\/\/mediccreview.org\/soberana-cuba-covid-19-vaccine-candidates\/."},{"key":"ref_25","unstructured":"Precisionvaccinations (2022, May 23). CorbeVax COVID-19 Vaccine. Available online: https:\/\/www.precisionvaccinations.com\/vaccines\/corbevax-covid-19-vaccine."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/j.vaccine.2005.01.033","article-title":"Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets","volume":"23","author":"Czub","year":"2005","journal-title":"Vaccine"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1086\/427242","article-title":"Development and Characterization of a Severe Acute Respiratory Syndrome\u2013Associated Coronavirus\u2013Neutralizing Human Monoclonal Antibody That Provides Effective Immunoprophylaxis in Mice","volume":"191","author":"Greenough","year":"2005","journal-title":"J. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jviromet.2005.03.021","article-title":"Monoclonal antibodies to SARS-associated coronavirus (SARS-CoV): Identification of neutralizing and antibodies reactive to S, N, M and E viral proteins","volume":"128","author":"Tripp","year":"2005","journal-title":"J. Virol. Methods"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1086\/500143","article-title":"Therapy with a Severe Acute Respiratory Syndrome\u2013Associated Coronavirus\u2013Neutralizing Human Monoclonal Antibody Reduces Disease Severity and Viral Burden in Golden Syrian Hamsters","volume":"193","author":"Roberts","year":"2006","journal-title":"J. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2217\/fvl.12.126","article-title":"Development of SARS vaccines and therapeutics is still needed","volume":"8","author":"Jiang","year":"2013","journal-title":"Future Virol."},{"key":"ref_31","unstructured":"NHS. \u201cSARS (Severe Acute Respiratory Syndrome)\u201d (2022, January 30). National Health Service. Available online: https:\/\/web.archive.org\/web\/20200309174230\/https:\/\/www.nhs.uk\/conditions\/sars\/."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Song, Z., Xu, Y., Bao, L., Zhang, L., Yu, P., Qu, Y., Zhu, H., Zhao, W., Han, Y., and Qin, C. (2019). From SARS to MERS, Thrusting Coronaviruses into the Spotlight. Viruses, 11.","DOI":"10.3390\/v11010059"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/490020a","article-title":"SARS veterans tackle coronavirus","volume":"490","author":"Butler","year":"2012","journal-title":"Nature"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s11684-016-0430-6","article-title":"Middle East respiratory syndrome coronavirus: A comprehensive review","volume":"10","author":"Shehata","year":"2016","journal-title":"Front. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1473-3099(19)30266-X","article-title":"Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: A phase 1, open-label, single-arm, dose-escalation trial","volume":"19","author":"Modjarrad","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.3389\/fmicb.2019.01781","article-title":"Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus","volume":"10","author":"Yong","year":"2019","journal-title":"Front. Microbiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1038\/mt.2012.7","article-title":"Increased Erythropoiesis in Mice Injected with Submicrogram Quantities of Pseudouridine-containing mRNA Encoding Erythropoietin","volume":"20","author":"Muramatsu","year":"2012","journal-title":"Mol. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1039\/C5BM00198F","article-title":"Biomaterials for mRNA delivery","volume":"3","author":"Islam","year":"2015","journal-title":"Biomater. Sci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"585354","DOI":"10.3389\/fimmu.2020.585354","article-title":"A Review of the Progress and Challenges of Developing a Vaccine for COVID-19","volume":"11","author":"Sharma","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.immuni.2021.07.017","article-title":"Accelerated COVID-19 vaccine development: Milestones, lessons, and prospects","volume":"54","author":"Bok","year":"2021","journal-title":"Immunity"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41586-021-03738-2","article-title":"SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses","volume":"596","author":"Turner","year":"2021","journal-title":"Nature"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/d41573-020-00151-8","article-title":"Evolution of the COVID-19 vaccine development landscape","volume":"19","author":"Le","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"5407","DOI":"10.1038\/s41467-021-25478-7","article-title":"The SARS-CoV-2 spike protein is vulnerable to moderate electric fields","volume":"12","author":"Arbeitman","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals","volume":"181","author":"Grifoni","year":"2020","journal-title":"Cell"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e00647-20","DOI":"10.1128\/JVI.00647-20","article-title":"The Nucleocapsid Protein of SARS-CoV-2: A Target for Vaccine Development","volume":"94","author":"Dutta","year":"2020","journal-title":"J. Virol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"msab292","DOI":"10.1093\/molbev\/msab292","article-title":"The neighborhood of the Spike gene is a hotspot for modular intertypic homologous and non-homologous recombination in Coronavirus genomes","volume":"39","author":"Nikolaidis","year":"2021","journal-title":"Mol. Biol. Evol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/d41573-020-00073-5","article-title":"The COVID-19 vaccine development landscape","volume":"19","author":"Thanh","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.chom.2020.04.021","article-title":"The Challenges of Vaccine Development against a New Virus during a Pandemic","volume":"27","author":"Diamond","year":"2020","journal-title":"Cell Host Microbe"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"a209","DOI":"10.1107\/S0108767320097937","article-title":"Structure-based design of prefusion-stabilized SARS-CoV-2 spikes","volume":"76","author":"McLellan","year":"2020","journal-title":"Acta Crystallogr. Sect. A Found. Adv."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1111\/all.14364","article-title":"Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19","volume":"75","author":"Azkur","year":"2020","journal-title":"Allergy"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"12370","DOI":"10.1021\/acsnano.0c06109","article-title":"Engineering Antiviral Vaccines","volume":"14","author":"Zhou","year":"2020","journal-title":"ACS Nano"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1126\/science.abb7015","article-title":"Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2","volume":"368","author":"Shi","year":"2020","journal-title":"Science"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.chom.2020.03.023","article-title":"Infection and rapid transmission of SARS-CoV-2 in ferrets","volume":"27","author":"Kim","year":"2020","journal-title":"Cell Host Microbe"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/s41467-020-15562-9","article-title":"Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV","volume":"11","author":"Ou","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.virol.2006.11.027","article-title":"The intracellular sites of early replication and budding of SARS-coronavirus","volume":"361","author":"Stertz","year":"2007","journal-title":"Virology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"16202","DOI":"10.1074\/jbc.M109.008227","article-title":"Severe acute respiratory syndrome coronavirus M protein inhibits type I interferon production by impeding the formation of TRAF3.TANK.TBK1\/IKKepsilon complex","volume":"284","author":"Siu","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/08830185.2020.1756284","article-title":"Can melatonin reduce the severity of COVID-19 pandemic?","volume":"39","author":"Shneider","year":"2020","journal-title":"Int. Rev. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.hjc.2020.03.002","article-title":"The Greek study in the effects of colchicine in COVID-19 complications prevention (GRECCO-19 study): Rationale and study design","volume":"61","author":"Deftereos","year":"2020","journal-title":"Hellenic J. Cardiol."},{"key":"ref_60","first-page":"327","article-title":"Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVID-19 or SARS-CoV-2): Anti-inflammatory strategies","volume":"34","author":"Conti","year":"2020","journal-title":"J. Biol. Regul. Homeost Agents"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s40259-020-00412-3","article-title":"In Vivo Delivery of Nucleic Acid-Encoded Monoclonal Antibodies","volume":"34","author":"Patel","year":"2020","journal-title":"BioDrugs"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41586-020-2286-9","article-title":"A SARS-CoV-2 protein interaction map reveals targets for drug repurposing","volume":"583","author":"Gordon","year":"2020","journal-title":"Nature"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"152072","DOI":"10.1016\/j.scitotenv.2021.152072","article-title":"CD147-spike protein interaction in COVID-19: Get the ball rolling with a novel receptor and therapeutic target","volume":"808","author":"Behl","year":"2022","journal-title":"Sci. Total Environ."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"17411","DOI":"10.3390\/ijms151017411","article-title":"The biological function and clinical utilization of CD147 in human diseases: A review of the current scientific literature","volume":"15","author":"Xiong","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s12015-020-09976-7","article-title":"CD147 as a target for COVID-19 treatment: Suggested effects of azithromycin and stem cell engagement","volume":"16","author":"Ulrich","year":"2020","journal-title":"Stem Cell Rev. Rep."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jcv.2019.08.009","article-title":"Influenza virus-specific CD4+ and CD8+ T cell-mediated immunity induced by infection and vaccination","volume":"119","author":"Jansen","year":"2019","journal-title":"J. Clin. Virol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41591-020-0897-1","article-title":"Antibody responses to SARS-CoV-2 in patients with COVID-19","volume":"26","author":"Long","year":"2020","journal-title":"Nat. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1111\/all.14360","article-title":"SARS-CoV-2 immunogenicity at the crossroads","volume":"75","author":"Karamloo","year":"2020","journal-title":"Allergy"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.chom.2020.03.002","article-title":"A sequence homology and bioinformatic approach can predict candidate targets for immune responses to SARS-CoV-2","volume":"27","author":"Grifoni","year":"2020","journal-title":"Cell Host Microbe"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Ahmed, S.F., Quadeer, A.A., and McKay, M.R. (2020). Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. Viruses, 12.","DOI":"10.1101\/2020.02.03.933226"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/j.vaccine.2016.02.063","article-title":"Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection","volume":"34","author":"Ng","year":"2016","journal-title":"Vaccine"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"100766","DOI":"10.1016\/j.nantod.2019.100766","article-title":"Three decades of messenger RNA vaccine development","volume":"28","author":"Verbeke","year":"2019","journal-title":"Nano Today"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 vaccines in development","volume":"586","author":"Krammer","year":"2020","journal-title":"Nature"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.addr.2020.12.008","article-title":"Non-viral COVID-19 vaccine delivery systems","volume":"169","author":"Park","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.ymthe.2019.02.012","article-title":"Delivering the messenger: Advances in technologies for therapeutic mRNA delivery","volume":"27","author":"Kowalski","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_76","unstructured":"CDC 2021 (2022, February 25). COVID-19 ACIP Vaccine Recommendations, Available online: https:\/\/www.cdc.gov\/vaccines\/hcp\/acip-recs\/vacc-specific\/covid-19.html."},{"key":"ref_77","unstructured":"EC European commission (2022, February 25). Safe COVID-19 Vaccines for Europeans. Available online: https:\/\/ec.europa.eu\/info\/live-work-travel-eu\/coronavirus-response\/safe-covid-19-vaccines-europeans_en."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1111\/ajt.16516","article-title":"Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine\u2014United States, December 14\u201323, 2020","volume":"21","author":"Shimabukuro","year":"2021","journal-title":"Am. J. Transplant."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.ymthe.2021.01.030","article-title":"Allergic reactions and anaphylaxis to LNP-based COVID-19 vaccines","volume":"29","author":"Moghimi","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.addr.2020.12.006","article-title":"Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection","volume":"169","author":"Batty","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"17056","DOI":"10.1038\/natrevmats.2017.56","article-title":"Tools for translation: Non-viral materials for therapeutic mRNA delivery","volume":"2","author":"Hajj","year":"2017","journal-title":"Nat. Rev. Mater."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.4161\/rna.22269","article-title":"Developing mRNA-vaccine technologies","volume":"9","author":"Schlake","year":"2012","journal-title":"RNA Biol."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Xu, S., Yang, K., Li, R., and Zhang, L. (2020). mRNA Vaccine Era\u2014Mechanisms, Drug Platform and Clinical Prospection. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21186582"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41541-021-00292-w","article-title":"SARS-CoV-2 vaccines strategies: A comprehensive review of phase 3 candidates","volume":"6","author":"Kyriakidis","year":"2021","journal-title":"NPJ Vaccines"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of Protection Induced by Vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.immuni.2016.09.001","article-title":"Germinal Center B Cell Dynamics","volume":"45","author":"Mesin","year":"2016","journal-title":"Immunity"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.immuni.2010.10.008","article-title":"From Vaccines to Memory and Back","volume":"33","author":"Sallusto","year":"2010","journal-title":"Immunity"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1056\/NEJMoa066092","article-title":"Duration of Humoral Immunity to Common Viral and Vaccine Antigens","volume":"357","author":"Amanna","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41586-020-2456-9","article-title":"Convergent antibody responses to SARS-CoV-2 in convalescent individuals","volume":"584","author":"Robbiani","year":"2020","journal-title":"Nature"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41586-020-2381-y","article-title":"A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2","volume":"584","author":"Shi","year":"2020","journal-title":"Nature"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.immuni.2020.07.019","article-title":"A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice","volume":"53","author":"Hogan","year":"2020","journal-title":"Immunity"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.immuni.2020.11.009","article-title":"SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation","volume":"53","author":"Lederer","year":"2020","journal-title":"Immunity"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness","volume":"586","author":"Corbett","year":"2020","journal-title":"Nature"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Vogel, A.B., Kanevsky, I., Che, Y., Swanson, K.A., Muik, A., Vormehr, M., Kranz, L.M., Walzer, K.C., Hein, S., and G\u00fcler, A. (2020). A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates. bioRxiv.","DOI":"10.1101\/2020.09.08.280818"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41541-021-00311-w","article-title":"mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents","volume":"6","author":"Rauch","year":"2021","journal-title":"NPJ Vaccines"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.cell.2020.07.024","article-title":"A Thermostable mRNA Vaccine against COVID-19","volume":"182","author":"Zhang","year":"2020","journal-title":"Cell"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/s41422-020-0387-5","article-title":"A Novel Receptor-Binding Domain (RBD)-Based MRNA Vaccine against SARS-CoV-2","volume":"30","author":"Tai","year":"2020","journal-title":"Cell Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41586-020-2787-6","article-title":"Animal models for COVID-19","volume":"586","author":"Dowling","year":"2020","journal-title":"Nature"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/s41422-020-00392-7","article-title":"A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice","volume":"30","author":"Lu","year":"2020","journal-title":"Cell Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41586-021-03841-4","article-title":"Rapid and stable mobilization of CD8+ T cells by SARS-CoV-2 mRNA vaccine","volume":"597","author":"Oberhardt","year":"2021","journal-title":"Nature"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines\u2014A new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Kumar, S., Nyodu, R., Maurya, V.K., and Saxena, S.K. (2020). Morphology, genome organization, replication, and pathogenesis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Coronavirus Dis.","DOI":"10.1007\/978-981-15-4814-7_3"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/jmv.25681","article-title":"Emerging coronaviruses: Genome structure, replication, and pathogenesis","volume":"92","author":"Chen","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41577-020-00436-4","article-title":"Not just antibodies: B cells and T cells mediate immunity to COVID-19","volume":"20","author":"Cox","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Bettini, E., and Locci, M. (2021). SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond. Vaccines, 9.","DOI":"10.3390\/vaccines9020147"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.2147\/IDR.S315727","article-title":"Overview of the Main Anti-SARS-CoV-2 Vaccines: Mechanism of Action, Efficacy and Safety","volume":"14","author":"Mascellino","year":"2021","journal-title":"Infect. Drug Resist."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"eabf4063","DOI":"10.1126\/science.abf4063","article-title":"Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection","volume":"371","author":"Dan","year":"2021","journal-title":"Science"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(21)00238-5","article-title":"Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: A longitudinal, population-level, cross-sectional study","volume":"397","author":"He","year":"2021","journal-title":"Lancet."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jaci.2017.12.971","article-title":"Vaccine-associated hypersensitivity","volume":"141","author":"McNeil","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and Immunogenicity of Two RNA-Based COVID-19 Vaccine Candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_111","unstructured":"FDA 2021a (2022, February 06). Vaccine Pfizer Data Sheet. Fact Sheet for Healthcare Providers Administrating Vaccines (Vaccination Providers) Emergency Use Authorization (EUA) of Pfizer\/BioNTech COVID-19 Vaccine to Prevent Coronavirus Disease 2019 (COVID-19), Available online: https:\/\/www.fda.gov\/media\/144413\/download."},{"key":"ref_112","unstructured":"FDA 2021b (2022, February 06). Vaccine Moderna Data Sheet. Fact Sheet for Healthcare Providers Administrating (EUA) of Vaccines (Vaccination Providers) Emergency Use Authorization of Moderna COVID-19 Vaccine to Prevent Coronavirus Disease 2019 (COVID-19), Available online: https:\/\/www.fda.gov\/media\/144637\/download."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2021.01.007","article-title":"Adaptive immunity to SARS-CoV-2 and COVID-19","volume":"184","author":"Sette","year":"2021","journal-title":"Cell"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Pai, M., Schull, M., Razak, F., Maltsev, A., Miller, K.J., Razak, F., Schull, M., Schwartz, B., Stall, N.M., and Steiner, R. (2020). Vaccine\u2013induced prothrombotic immune thrombocytopenia (VIPIT) following AstraZeneca COVID-19 vaccination. Sci. Briefs, Available online: http:\/\/covid19-sciencetable.ca\/science-briefs.","DOI":"10.47326\/ocsat.2021.02.17.1.0"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1016\/j.vaccine.2021.03.058","article-title":"Projecting the impact of a two-dose COVID-19 vaccination campaign in Ontario, Canada","volume":"39","author":"Vilches","year":"2021","journal-title":"Vaccine"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/S0140-6736(21)00628-0","article-title":"Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 VOC 202012\/01 (B.1.1.7), an exploratory analysis of a randomised controlled trial","volume":"397","author":"Emary","year":"2021","journal-title":"Lancet"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S0140-6736(20)32623-4","article-title":"Oxford\u2013AstraZeneca COVID-19 vaccine efficacy","volume":"397","author":"Knoll","year":"2021","journal-title":"Lancet"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against COVID-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1001\/jama.2021.2927","article-title":"The Johnson & Johnson Vaccine for COVID-19","volume":"325","author":"Livingston","year":"2021","journal-title":"JAMA"},{"key":"ref_121","first-page":"680","article-title":"Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine\u2014United States, March\u2013April 2021","volume":"70","author":"Shay","year":"2021","journal-title":"MMWR"},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"(2021). Novavax and Janssen Report Positive Phase III Results for COVID-19 Vaccine Candidates. Clin. OMICs, 8, 10.","DOI":"10.1089\/clinomi.08.02.14"},{"key":"ref_123","unstructured":"National Institute of Allergy and Infectious Disease (NIAID) and Pharmaceutical Janssen Companies from the U.S. Department of Health and Human Services\u2019 (2022, February 06). Janssen Investigational COVID-19 Vaccine: Interim Analysis of Phase 3 Clinical Data Released, Available online: https:\/\/www.nih.gov\/news-events\/news-releases\/janssen-investigational-covid-19-vaccine-interim-analysis-phase-3-clinical-data-released."},{"key":"ref_124","unstructured":"Vaccine Janssen Data Sheet 2021 (2022, February 06). John Galloway (King\u2019s College London). Available online: https:\/\/www.janssenlabels.com\/emergency-use-authorization\/Janssen+COVID-19+Vaccine-HCP-fact-sheet.pdf."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S0140-6736(21)00191-4","article-title":"Sputnik V COVID-19 vaccine candidate appears safe and effective","volume":"397","author":"Jones","year":"2021","journal-title":"Lancet"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: An interim analysis of a randomised controlled phase 3 trial in Russia","volume":"397","author":"Logunov","year":"2021","journal-title":"Lancet"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41392-020-00352-y","article-title":"A systematic review of SARS-CoV-2 vaccine candidates","volume":"5","author":"Dong","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.ijbiomac.2021.08.076","article-title":"SARS-CoV-2 (COVID-19) vaccines structure, mechanisms and effectiveness: A review","volume":"188","author":"Fathizadeh","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"101422","DOI":"10.1016\/j.smim.2020.101422","article-title":"The immunology of SARS-CoV-2 infections and vaccines","volume":"50","author":"Grigoryan","year":"2020","journal-title":"Semin. Immunol."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Speiser, D., and Bachmann, M. (2020). COVID-19: Mechanisms of Vaccination and Immunity. Vaccines, 8.","DOI":"10.3390\/vaccines8030404"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.cell.2020.06.008","article-title":"Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2","volume":"182","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Talukder, A., Kalita, C., Neog, N., Goswami, C., Sarma, M., and Hazarika, I. (2022). A comparative analysis on the safety and efficacy of Covaxin versus other vaccines against COVID-19: A review. Z. F\u00fcr Nat. C.","DOI":"10.1515\/znc-2021-0301"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/S0140-6736(21)02000-6","article-title":"Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): Interim results of a randomised, double-blind, controlled, phase 3 trial","volume":"398","author":"Ella","year":"2021","journal-title":"Lancet"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41577-021-00578-z","article-title":"Immunological mechanisms of vaccine-induced protection against COVID-19 in humans","volume":"21","author":"Sadarangani","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"ref_135","first-page":"67","article-title":"Advances in the design and development of SARS-CoV-2 vaccines","volume":"8","author":"Peng","year":"2021","journal-title":"Mil. Med. Res."},{"key":"ref_136","first-page":"5","article-title":"Immunogenicity and protectivity of the peptide candidate vaccine against SARS-CoV-2","volume":"76","author":"Ryzhikov","year":"2021","journal-title":"Ann. Russ. Acad. Med. Sci."},{"key":"ref_137","first-page":"100989","article-title":"Safety and Immunogenicity of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine (MVC-COV1901) Adjuvanted With CpG 1018 and Aluminum Hydroxide in Healthy Adults: A Phase 1, Dose-Escalation Study","volume":"38","author":"Hsieh","year":"2021","journal-title":"SSRN Electron. J."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S1473-3099(21)00127-4","article-title":"Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: Two randomised, double-blind, placebo-controlled, phase 1 and 2 trials","volume":"21","author":"Yang","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/d41586-021-02216-z","article-title":"Iran hopes to defeat COVID with home-grown crop of vaccines","volume":"596","author":"Mallapaty","year":"2021","journal-title":"Nature"},{"key":"ref_140","unstructured":"Sasaki, S., and Okuda, K. (2000). The use of conventional immunologic adjuvants in DNA vaccine preparations. DNA Vaccines, Humana Press."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Waqas, M., Haider, A., Rehman, A., Qasim, M., Umar, A., Sufyan, M., Akram, H., Mir, A., Razzaq, R., and Rasool, D. (2021). Immunoinformatics and Molecular Docking Studies Predicted Potential Multiepitope-Based Peptide Vaccine and Novel Compounds against Novel SARS-CoV-2 through Virtual Screening. BioMed Res. Int., 2021.","DOI":"10.1155\/2021\/1596834"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/s41467-020-20653-8","article-title":"SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice","volume":"12","author":"Tian","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S0140-6736(21)00241-5","article-title":"Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: A phase 1, randomised, double-blind, placebo-controlled trial","volume":"397","author":"Richmond","year":"2021","journal-title":"Lancet"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"104236","DOI":"10.1016\/j.micpath.2020.104236","article-title":"Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2","volume":"145","author":"Kalita","year":"2020","journal-title":"Microb. Pathog."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"e05528","DOI":"10.1016\/j.heliyon.2020.e05528","article-title":"Designing spike protein (S-Protein) based multi-epitope peptide vaccine against SARS COVID-19 by immunoinformatics","volume":"6","author":"Singh","year":"2020","journal-title":"Heliyon"},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Behmard, E., Soleymani, B., Najafi, A., and Barzegari, E. (2020). Immunoinformatic design of a COVID-19 subunit vaccine using entire structural immunogenic epitopes of SARS-CoV-2. Sci. Rep.","DOI":"10.21203\/rs.3.rs-27260\/v1"},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Machado, L., and Ottolini, B. (2015). An Evolutionary History of Defensins: A Role for Copy Number Variation in Maximizing Host Innate and Adaptive Immune Responses. Front. Immunol.","DOI":"10.3389\/fimmu.2015.00115"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"39021","DOI":"10.1074\/jbc.M103830200","article-title":"The Structure of Human \u03b2-Defensin-1","volume":"276","author":"Hoover","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/jid.2012.319","article-title":"Human Beta-Defensin 3 Induces Maturation of Human Langerhans Cell\u2013Like Dendritic Cells: An Antimicrobial Peptide that Functions as an Endogenous Adjuvant","volume":"133","author":"Ferris","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1146\/annurev.physiol.64.081501.134340","article-title":"\u03b2-Defensins in Lung Host Defense","volume":"64","author":"Schutte","year":"2002","journal-title":"Annu. Rev. Physiol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12985-018-1035-2","article-title":"Human \u03b2-defensin 2 plays a regulatory role in innate antiviral immunity and is capable of potentiating the induction of antigen-specific immunity","volume":"15","author":"Kim","year":"2018","journal-title":"Virol. J."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"103197","DOI":"10.1016\/j.ebiom.2020.103197","article-title":"Adjuvanted SARS-CoV-2 spike protein elicits neutralizing antibodies and CD4 T cell responses after a single immunization in mice","volume":"63","author":"Sheward","year":"2021","journal-title":"EBioMedicine"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"599587","DOI":"10.3389\/fimmu.2020.599587","article-title":"CoVaccine HT\u2122 Adjuvant Potentiates Robust Immune Responses to Recombinant SARS-CoV-2 Spike S1 Immunization","volume":"11","author":"Haun","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.tips.2017.06.002","article-title":"An Overview of Novel Adjuvants Designed for Improving Vaccine Efficacy","volume":"38","author":"Bonam","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nri1329","article-title":"Immunotherapeutic uses of CpG oligodeoxynucleotides","volume":"4","author":"Klinman","year":"2004","journal-title":"Nat. Rev. Immunol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/08830180600743057","article-title":"Adjuvant Activity of CpG Oligodeoxynucleotides","volume":"25","author":"Klinman","year":"2006","journal-title":"Int. Rev. Immunol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1586\/erv.10.174","article-title":"CpG DNA as a vaccine adjuvant","volume":"10","author":"Bode","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00011-020-01377-3","article-title":"SARS-CoV-2 will constantly sweep its tracks: A vaccine containing CpG motifs in \u2018lasso\u2019 for the multi-faced virus","volume":"69","author":"Oberemok","year":"2020","journal-title":"Inflamm. Res."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1126\/science.abf3995","article-title":"Insights from SARS-CoV-2 sequences","volume":"371","author":"Martin","year":"2021","journal-title":"Science"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.cmi.2021.03.011","article-title":"Severe acute respiratory syndrome coronavirus 2 escape mutants and protective immunity from natural infections or immunizations","volume":"27","author":"Cunha","year":"2021","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"e01140-21","DOI":"10.1128\/mBio.01140-21","article-title":"Evolution, Mode of Transmission, and Mutational Landscape of Newly Emerging SARS-CoV-2 Variants","volume":"12","author":"Chakraborty","year":"2021","journal-title":"mBio"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"e2270","DOI":"10.1002\/rmv.2270","article-title":"Present variants of concern and variants of interest of severe acute respiratory syndrome coronavirus 2: Their significant mutations in S-glycoprotein, infectivity, re-infectivity, immune escape and vaccines activity","volume":"32","author":"Chakraborty","year":"2021","journal-title":"Rev. Med. Virol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1002\/jmv.27633","article-title":"Omicron (B.1.1.529) variant of SARS-CoV-2: Concerns, challenges, and recent updates","volume":"94","author":"Mohapatra","year":"2022","journal-title":"J. Med. Virol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.coph.2021.11.006","article-title":"Emerging mutations in the SARS-CoV-2 variants and their role in antibody escape to small molecule-based therapeutic resistance","volume":"62","author":"Chakraborty","year":"2022","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"801522","DOI":"10.3389\/fimmu.2022.801522","article-title":"A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations","volume":"13","author":"Chakraborty","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1001\/jama.2021.1114","article-title":"SARS-CoV-2 Vaccines and the Growing Threat of Viral Variants","volume":"325","author":"Moore","year":"2021","journal-title":"JAMA"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"9035","DOI":"10.1007\/s00253-021-11676-2","article-title":"D614G mutation and SARS-CoV-2: Impact on S-protein structure, function, infectivity, and immunity","volume":"105","author":"Bhattacharya","year":"2021","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.omtn.2021.07.011","article-title":"D614G mutation eventuates in all VOI and VOC in SARS-CoV-2: Is it part of the positive selection pioneered by Darwin?","volume":"26","author":"Chakraborty","year":"2021","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41586-021-03412-7","article-title":"Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies","volume":"593","author":"Collier","year":"2021","journal-title":"Nature"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41586-021-03398-2","article-title":"Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7","volume":"593","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"eabo2202","DOI":"10.1126\/sciimmunol.abo2202","article-title":"Divergent SARS-CoV-2 Omicron\u2013reactive T and B cell responses in COVID-19 vaccine recipients","volume":"7","author":"Geers","year":"2022","journal-title":"Sci. Immunol."},{"key":"ref_172","unstructured":"(2022, May 24). More Than 12.2 Billion Shots Given: COVID-19 Tracker. Available online: https:\/\/www.bloomberg.com\/graphics\/covid-vaccine-tracker-global-distribution\/."},{"key":"ref_173","unstructured":"Ritchie, H., Mathieu, E., Rod\u00e9s-Guirao, L., Appel, C., Giattino, C., Ortiz-Ospina, E., Hasell, J., Macdonald, B., Beltekian, D., and Roser, M. (2022, May 24). Coronavirus Pandemic (COVID-19). Our World Data. Available online: https:\/\/ourworldindata.org\/covid-vaccinations."},{"key":"ref_174","unstructured":"(2022, May 24). CDC: New Omicron Subvariant Takes Over as Dominant Coronavirus Strain. Available online: \/\/www.usnews.com\/news\/national-news\/articles\/2022-05-24\/cdc-new-omicron-subvariant-ba-2-12-1-takes-over-as-dominant-coronavirus-strain."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/imcb.12511","article-title":"The benefit of boosters: Diversity and inclusion in the COVID-19 memory response","volume":"100","author":"Hartley","year":"2022","journal-title":"Immunol. Cell Biol."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/7\/1464\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:36:47Z","timestamp":1760139407000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/7\/1464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,21]]},"references-count":175,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["biomedicines10071464"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines10071464","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,21]]}}}